{"id":93241,"date":"2016-07-20T18:42:27","date_gmt":"2016-07-20T22:42:27","guid":{"rendered":"http:\/\/countingpips.com\/?p=93241"},"modified":"2016-07-20T18:42:27","modified_gmt":"2016-07-20T22:42:27","slug":"nobilis-moves-forward-with-new-president-and-new-canaccord-coverage","status":"publish","type":"post","link":"https:\/\/www.investmacro.com\/forex\/2016\/07\/nobilis-moves-forward-with-new-president-and-new-canaccord-coverage\/","title":{"rendered":"Nobilis Moves Forward with New President and New Canaccord Coverage"},"content":{"rendered":"
July 20, 2016<\/div>
\r\n<\/div><\/div>

By The Life Science Report<\/strong><\/p>\n

https:\/\/www.streetwisereports.com\/pub\/na\/17045<\/a><\/p>\n

Under the guidance of newly appointed president Kenneth Efird, Nobilis Health Corp. plans to continue to roll out new products and optimize its marketing strategy.<\/p>\n

Kenneth Efird will oversee Nobilis Health Corp.’s (HLTH:NYSE; NHC:TSX)<\/a> operating units across the nation, focusing on execution of the company’s strategic plan, according to a press release<\/a> issued on July 11. Prior to
\nstepping in as president, Efird had served as chief operating officer and chief business development officer at Nobilis, which operates surgical hospitals,\u00a0physician practices and ambulatory surgical centers in Texas and Phoenix.<\/p>\n

Since coming on board in 2005, Efird has overseen various aspects of the company’s business, including clinical operations, sales and “the rollout of a new\u00a0marketing strategy, which includes the integration of Athas technologies and the expansion of Nobilis’ portfolio of brands,” according to the company.<\/p>\n

Neil Maruoka, an analyst with Canaccord Genuity who initiated coverage on Nobilis on July 13, pointed out that Athas, the company’s “marketing arm,” is “a key\u00a0differentiator and organic growth engine. . .Through its targeted marketing, we believe that Athas has the ability to drive higher case volumes and higher
\nrevenue per procedure through Nobilis’ facilities.”<\/p>

\r\n
\r\n

Free Reports:<\/p><\/div>\r\n

\r\n

<\/a>\r\n\t Get Our Free Metatrader 4 Indicators<\/u><\/b><\/a> - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter<\/p>

\r\n
\r\n
\r\n

<\/a>\r\n\t Get our Weekly Commitment of Traders Reports<\/u><\/b><\/a> - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.<\/p>

\r\n<\/div>\r\n

\r\n
<\/div>\n

Canaccord also views Nobilis’ surgical facilities “to be steady businesses, providing strong cash generation to underpin our valuation.” Maruoka has a rated\u00a0Nobilis a Buy with a price target of $4.50 per share.<\/p>\n

Nobilis (then Northstar Health) acquired Athas Health, a Dallas-based marketing firm, in late 2014. The Athas technology, according to analyst William\u00a0Sutherland of Emerging Growth Equities, provides Nobilis with an “end-to-end concierge model that begins with direct-to-consumer marketing through\u00a0post-surgical support.”<\/p>\n

Back in May, analyst Dana Hambly of Stephens noted that Nobilis’ recently launched subsidiary Concertis, a platform that “negotiates bundled payments for\u00a0surgical procedures with payers covering pre- and post-operative services. . .should start driving case growth in [H2], improving on already solid organic\u00a0growth.”<\/p>\n

According to Nobilis, Efird has “played a significant role in the integration of acquisitions,” which included three new facilities in 2015 and the launch of\u00a0Concertis.<\/p>\n

“Throughout the past several years of tremendous growth, Kenneth has built an impressive track record of operational and strategic accomplishments,” said\u00a0company CEO Harry Fleming in the press release.<\/p>\n

\n

Read what other experts are saying about:<\/p>\n